Antiplatelet drugs and liver fibrosis
Liver fibrosis results from an imbalance between extracellular matrix formation and degradation. The background of liver fibrosis is chronic inflammation and subsequent microcirculation disturbance including microthrombosis. Platelets actively participate in liver fibrosis not only as a part of the...
Main Authors: | Pamela Czajka, Adam Przybyłkowski, Anna Nowak, Marek Postula, Marta Wolska, Dagmara Mirowska-Guzel, Anna Czlonkowska, Ceren Eyileten |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-02-01
|
Series: | Platelets |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09537104.2021.1883574 |
Similar Items
-
Complexities of oral antiplatelet drugs use in pregnancy
by: Antonijević Nebojša M., et al.
Published: (2020-01-01) -
MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
by: Justyna Pordzik, et al.
Published: (2021-05-01) -
Effects of Antiplatelet Drugs on Platelet-Dependent Coagulation Reactions
by: Ivan A. Muravlev, et al.
Published: (2023-07-01) -
RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01) -
Basic principles of antiplatelet therapy from the perspective of new recommendations
by: M. G Bubnova, et al.
Published: (2017-12-01)